[시장보고서]미국의 측면 유동 분석 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 최종 용도별, 부문 예측(2025-2033년)

미국의 측면 유동 분석 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Lateral Flow Assay Market Size, Share & Trends Analysis Report By Product, By Application, By Technique, By End use, And Segment Forecasts, 2025 - 2033

상품코드 : 1772200

리서치사 : Grand View Research

발행일 : 2025년 06월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,612,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,059,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,954,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

미국의 측면 유동 분석 시장 동향 :

미국의 측면 유동 분석 시장 규모는 2024년에 28억 2,000만 달러가 되고, 2033년에는 46억 3,000만 달러에 이를 것으로 예측되며, 2025년부터 2033년까지의 CAGR은 6.08%로 성장할 전망입니다. 전염병의 유행이 증가하면서 전 세계 공중 보건 시스템에 막대한 압박이 가해지고 있습니다. 도시화, 상호 연결성, 항생제 내성, 기후 변화의 영향이 증가함에 따라 전문가들은 감염병 감시, 예방, 진단 능력 강화의 시급성을 강조하고 있습니다. 전 세계적으로 전염병이 증가하면서 신속한 진단 솔루션이 필요하게 되어 LFA(측면 흐름 분석) 시장이 크게 촉진되고 있습니다. 미국 질병통제예방센터(CDC)에 따르면, 미국의 결핵(TB) 사례는 2022년 7,874건에서 2024년 1만 347건으로 증가하여 공중 보건에 중대한 도전 과제가 되고 있습니다.

모기 매개 질병 검사 부문은 웨스트 나일 바이러스(WNV), 뎅기열, 치쿤구냐, 지카 바이러스, 말라리아, 황열병 등 모기 매개 감염의 유행이 증가함에 따라 상당한 성장을 보일 것으로 예상됩니다. 이러한 질병의 발병률이 증가함에 따라, 특히 발병이 쉬운 지역에서 신속하고 효율적인 진단 솔루션에 대한 수요가 높아지고 있습니다. 미국 질병통제예방센터(CDC)에 따르면, 웨스트 나일 바이러스(WNV)는 미국에서 풍토병으로 자리 잡았으며, 48개 주와 워싱턴 D.C.에서 여름과 가을에 주로 발생하고 있습니다. 2024년 11월 기준 CDC는 WNV 사례 1,466건을 기록했으며, 2022년에는 913건의 인간 감염 사례가 보고되었으며 이 중 70%는 신경침습성, 30%는 비신경침습성으로 분류되었습니다. 모기 매개 질환의 증가하는 부담과 코로나19 및 원숭이두창과 같은 지속적인 건강 위기 상황은 효과적인 진단 및 감시 조치의 시급성을 강조합니다.

공중 보건 이니셔티브도 시장 확대에 중요한 역할을 합니다. CDC의 인플루엔자 부문 국제 프로그램은 인플루엔자 퇴치를 위한 감시, 유행병 대비, 연구 및 예방 접종 프로그램에 중점을 두고 있습니다. 또한, 전국 카운티 및 시 보건 공무원 협회는 인플루엔자 예방 및 통제를 위해 지역 보건 부서를 지원합니다.

미국의 측면 유동 분석 시장 : 용도 변동 분석
용도별(2021-2033년)
임상시험
- 감염증 검사
- 심장 마커 검사
- 임신과 생식능력 검사
- 콜레스테롤 검사/지질 프로파일
- 남용 약물 검사
- 기타 임상 검사
수의 진단
식품안전 및 환경시험
의약품 개발과 품질시험

제6장 미국의 측면 유동 분석 시장 : 기술 추정 및 동향 분석

미국의 측면 유동 분석 시장 : 기술 변동 분석
기술별(2021-2033년)
샌드위치 분석
경쟁 분석
멀티플렉스 검출 분석

제7장 미국의 측면 유동 분석 시장 : 최종 용도의 추정 및 동향 분석

미국의 측면 유동 분석 시장 : 최종 용도 변동 분석
최종 용도별(2021-2033년)
병원 및 진료소
진단 실험실
홈케어
제약 및 바이오기술 기업
기타 용도

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 프로파일
- Abbott
- Bio-Rad Laboratories, Inc
- Siemens Healthineers AG
- BIOMERIEUX
- BD
- QIAGEN
- QuidelOrtho Corporation
- F. Hoffmann-La Roche
- DH Life Sciences, LLC.
- Quest Diagnostics

HBR

영문 목차

영문목차

U.S. Lateral Flow Assay Market Trends:

The U.S. lateral flow assay market size was valued at USD 2.82 billion in 2024 and is projected to reach USD 4.63 billion by 2033, growing at a CAGR of 6.08% from 2025 to 2033. The rising prevalence of infectious diseases places immense pressure on public health systems worldwide. With increasing urbanization, interconnectivity, antimicrobial resistance, and the rising impact of climate change, experts stress the urgent need for enhanced infectious disease surveillance, prevention, and diagnostic capabilities. The global rise in infectious diseases significantly drives the lateral flow assays (LFA) market by necessitating rapid diagnostic solutions. According to the Centers for Disease Control and Prevention (CDC), tuberculosis (TB) cases in the U.S. increased from 7,874 in 2022 to 10,347 in 2024, reflecting a notable public health challenge.

The mosquito-borne disease testing segment is projected to experience significant growth due to the rising prevalence of mosquito-borne infections, including West Nile virus (WNV), dengue, chikungunya, Zika virus, malaria, and yellow fever. The increasing incidence of these diseases has heightened the demand for rapid and efficient diagnostic solutions, particularly in regions prone to outbreaks. According to the Centers for Disease Control and Prevention (CDC), West Nile virus (WNV) has become endemic in the U.S., with cases reported in all 48 contiguous states and the District of Columbia, predominantly during the summer and fall months. As of November 2024, the CDC recorded 1,466 cases of WNV, while in 2022, 913 human cases were reported, with 70% classified as neuroinvasive and 30% as non-neuroinvasive. The increasing burden of mosquito-borne diseases, alongside ongoing health crises such as COVID-19 and monkeypox, underscores the urgent need for effective diagnostic and surveillance measures.

Public health initiatives also play a crucial role in market expansion. The CDC's Influenza Division International Program focuses on surveillance, pandemic preparedness, research, and vaccination programs to combat influenza. Additionally, the National Association of County and City Health Officials supports local health departments in influenza prevention and control.

U.S. Lateral Flow Assay Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. lateral flow assay market report based on product, application, technique, and end use:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Kits & Reagents
Lateral Flow Readers
Benchtop Readers
Digital Readers
Application Outlook (Revenue, USD Million, 2021 - 2033)
Clinical Testing
- Infectious Disease Testing
- COVID-19
- Mosquito Borne Disease Testing
- Malaria Testing
- Dengue Testing
- Zika Testing
- Chikungunya Testing
- Others
- Influenza Testing
- Sexually Transmitted Infection Testing
- HIV Testing
- HPV Testing
- Chlamydia Testing
- Gonorrhea Testing
- Syphilis Testing
- Other STI Testing
- Hepatitis
- Tuberculosis
- Other Infectious Diseases
- Cardiac Marker Testing
- Troponin I and T Testing
- CK-MB Testing
- BNP and NT-Probnp Testing
- Myoglobin Testing
- D-Dimer Testing
- Other Cardiac Marker Tests
- Pregnancy & Fertility Testing
- Pregnancy Testing
- Fertility Testing
- Cholesterol Testing/Lipid Profile
- Drugs of Abuse Testing
- Other Clinical Tests
Veterinary Diagnostics
Food Safety & Environment Testing
Drug Development & Quality Testing
Technique Outlook (Revenue, USD Million, 2021 - 2033)
Sandwich Assays
Competitive Assays
Multiplex Detection Assays
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Clinics
Diagnostic Laboratories
Home Care
Pharmaceutical & Biotechnology Companies
Others

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Lateral Flow Assay Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
  - 3.3.1.1. Increasing prevalence of infectious diseases
  - 3.3.1.2. Technological advancements in lateral flow
  - 3.3.1.3. Growing adoption in homecare settings
- 3.3.2. Market Restraints Analysis
  - 3.3.2.1. Stringent Regulations
- 3.3.3. Market Opportunities Analysis
  - 3.3.3.1. Growing demand for Point-of-Care (POC) Testing
  - 3.3.3.2. Expanding applications beyond healthcare
- 3.3.4. Market Challenges Analysis
  - 3.3.4.1. Product Recalls
3.4. U.S. Lateral Flow Assay Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. U.S. Lateral Flow Assay Market: Product Estimates & Trend Analysis

4.1. U.S. Lateral Flow Assay Market: Product Movement Analysis
4.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Product 2024 & 2033 (USD Million)
4.3. Kits & Reagents
- 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Lateral Flow Readers
- 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Benchtop Readers
  - 4.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Digital Readers
  - 4.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Lateral Flow Assay Market: Application Estimates & Trend Analysis

5.1. U.S. Lateral Flow Assay Market: Application Movement Analysis
5.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Application 2024 & 2033 (USD Million)
5.3. Clinical Testing
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3.2. Infectious Disease Testing
  - 5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.2. COVID-19
    - 5.3.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.3. Mosquito Borne Disease Testing
    - 5.3.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.3.2. Malaria Testing
      - 5.3.2.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.3.3. Dengue Testing
      - 5.3.2.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.3.4. Zika Testing
      - 5.3.2.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.3.5. Chikungunya Testing
      - 5.3.2.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.3.6. Others
      - 5.3.2.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.4. Influenza Testing
    - 5.3.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.5. Sexually Transmitted Infection Testing
    - 5.3.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.5.2. HIV Testing
      - 5.3.2.5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.5.3. HPV Testing
      - 5.3.2.5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.5.4. Chlamydia Testing
      - 5.3.2.5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.5.5. Gonorrhea Testing
      - 5.3.2.5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.5.6. Syphilis Testing
      - 5.3.2.5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    - 5.3.2.5.7. Other STI Testing
      - 5.3.2.5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.6. Hepatitis
    - 5.3.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.7. Tuberculosis
    - 5.3.2.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.2.8. Other Infectious Diseases
    - 5.3.2.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3.3. Cardiac Marker Testing
  - 5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.3.2. Troponin I and T Testing
    - 5.3.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.3.3. CK-MB Testing
    - 5.3.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.3.4. BNP and NT-Probnp Testing
    - 5.3.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.3.5. Myoglobin Testing
    - 5.3.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.3.6. D-Dimer Testing
    - 5.3.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.3.7. Other Cardiac Marker Tests
    - 5.3.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3.4. Pregnancy & Fertility Testing
  - 5.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.4.2. Pregnancy Testing
    - 5.3.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.3.4.3. Fertility Testing
    - 5.3.4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3.5. Cholesterol Testing/Lipid Profile
  - 5.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3.6. Drugs of Abuse Testing
  - 5.3.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3.7. Other Clinical Tests
  - 5.3.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Veterinary Diagnostics
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Food Safety & Environment Testing
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Drug Development & Quality Testing
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Lateral Flow Assay Market: Technique Estimates & Trend Analysis

6.1. U.S. Lateral Flow Assay Market: Technique Movement Analysis
6.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by Technique 2024 & 2033 (USD Million)
6.3. Sandwich Assays
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Competitive Assays
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Multiplex Detection Assays
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Lateral Flow Assay Market: End Use Estimates & Trend Analysis

7.1. U.S. Lateral Flow Assay Market: End-use Movement Analysis
7.2. U.S. Lateral Flow Assay Market Estimates and Forecasts, by End-use 2024 & 2033 (USD Million)
7.3. Hospitals & Clinics
- 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Diagnostic Laboratories
- 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Home Care
- 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Pharmaceutical & Biotechnology Companies
- 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Other End-use
- 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Abbott
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Bio-Rad Laboratories, Inc
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Siemens Healthineers AG
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. BIOMERIEUX
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. BD
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. QIAGEN
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. QuidelOrtho Corporation
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. F. Hoffmann-La Roche
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. DH Life Sciences, LLC.
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Quest Diagnostics
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives